CD47 (also known as integrin-associated protein) is a member of the immunoglobulin superfamily that plays an important role in blood cell homeostasis and inflammation. By interacting with various beta integrins, CD47 modulates monocyte motility, leukocyte adhesion and migration, phagocytosis, and platelet activation (Brown and Frazier, 2001) . Furthermore, by interacting with various ligands, including thrombospondins (TSPs) and signal regulatory proteins, CD47 can also trigger cell death mechanisms in T cells (Manna and Frazier, 2003) , monocytes and dendritic cells (Johansson et al., 2004) , and leukemia cells (Mateo et al., 1999 (Mateo et al., , 2002 Saumet et al., 2005; Bras et al., 2007) .
Recently, CD47 has been found to also play a critical role in the central nervous system. Activation of CD47 signaling induced novel caspase-dependent and caspase-independent cell death mechanisms in neurons (Koshimizu et al., 2002; Xing et al., 2009) . Hence, in the context of stroke and brain injury, overactivation of the CD47 pathway may lead to multiple deleterious effects in brain. These would potentially include promotion of inflammation by enhancing neutrophil infiltration, secondary thrombosis by augmenting platelet aggregation, and parenchymal damage by triggering cell death in neurons. Recently, we showed that CD47 gene knockout reduced infarction after focal cerebral ischemia . Because CD47 can be found on endothelial cells, we decided to ask whether CD47 may also contribute to neurovascular dysfunction relevant to stroke and brain injury. Specifically, we assessed the role of CD47 signaling in cell death, inflammation and angiogenesis in cerebral endothelial cells in culture.
EDTA, L-glutamine, fetal bovine serum, horse serum, sodium pyruvate, minimum essential medium (MEM) nonessential amino acids, MEM vitamins, and antibiotics for cell culture were from Invitrogen (Carlsbad, CA). Growth factor-reduced Matrigel Matrix, collagen I, endothelial cell growth supplement, and NuSerum were purchased from BD Biosciences (San Jose, CA). TSP-1 was purchased from Calbiochem (San Diego, CA). 4N1K (KRFYVVMWKK) was from Sigma Genosys (The Woodlands, Texas), and was dissolved in sterile ddH 2 O at a concentration of 100 mg/ml as a stock solution. This stock was formed into aliquots and stored at 2808C. Cytotoxicity Detection Kit LDH (lactate dehydrogenase) was from Roche Diagnostics (Mannheim, Germany). Enzymelinked immunosorbent assay (ELISA) kits of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin were purchased from Thermo-Scientific/Pierce (Rockfold, IL). Heparin, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), and thymidine were from Sigma-Aldrich (St. Louis, MO).
Cerebral Endothelial Cell Cultures
All experiments were approved by Institutional Animal Care and Use Committee following the NIH Guide for the Use and Care of Laboratory Animals. Standard procedures were used to obtain mouse primary cerebral endothelial cells (Guo et al., 2008) . Briefly, primary mouse brain microvascular endothelial cells were cultured from the cerebrum of 3-5-week-old male wild-type or CD47 knockout mice, purified with anti-murine CD31 precoated M-450 Dynabeads (Dynal), and plated onto tissue culture dishes coated with collagen I in complete culture medium (DMEM/F-12 containing 10% fetal bovine serum [FBS] , 10% horse serum, 0.1 mg/ml endothelial cell growth supplement, 0.1 mg/ml heparin, and 100 units/ml penicillin/streptomycin). Mouse endothelial cells were split at a ratio of 1:2 and used at passages 2-3. To determine the effects of CD47 signaling, wild-type or CD47 knockout endothelial cells were incubated with different doses of TSP-1 (100, 500, and 1,000 ng/ml) for 24 hr. Cytotoxicity was evaluated with MTT assay (at least three times in triplicate). We also tested a human brain microvascular endothelial cell line, previously confirmed to express brain endothelial phenotypes (Callahan et al., 2004; Guo et al., 2008) . Endothelial cells were cultured in RPMI 1640 supplemented with 10% FBS, 10% NuSerum, 1mM sodium pyruvate, MEM nonessential amino acids, MEM vitamins, and 100 units/ml penicillin/ streptomycin, and used to study the effects of the CD47-specific peptide 4N1K. Endothelial cells were incubated with different amounts of 4N1K (25, 50, and 100 lg/ml) for 24 hr, and cytotoxicity was evaluated by the standard LDH release assay (at least three times in triplicate).
Adhesion Molecule ELISA Assays
Human brain microvascular endothelial cells were incubated with 500 ng/ml TSP-1 for various times (2, 4, or 8 hr). The levels of ICAM-1, VCAM-1, and E-selectin in culture supernatant were determined by ELISA kits, according to the manufacturer's instructions.
In Vitro Angiogenesis Assays
Cell migration and tube formation tests were used as indirect in vitro assays to assess angiogenesis. The human brain endothelial cell line was plated on 60-mm culture dishes at 90% confluence. A wound was made across the cells with a razor blade, then the cultures were washed with serum-free medium and further incubated in RPMI 1640 with 1% FBS, 1 mM thymidine, with or without 4N1K (100 lg/ml). Cells were allowed to migrate for 24 hr, then rinsed with PBS, followed by fixing with methanol and staining with Giemsa. The numbers of endothelial cells that moved across the injury line were counted as a standard marker of migration. Data were analyzed as a percentage of migration in untreated endothelial cells. The standard Matrigel assay was used to assess the spontaneous formation of capillary-like structures by the human brain endothelial cell line. Cells (6 3 10 4 cells/well) were seeded in 24-well plates previously coated with growth factor reduced Matrigel, and incubated at 378C for 18 hr with or without 4N1K. The degree of tube formation was determined by counting the number of tubes in four random fields from each well. Data were analyzed as a percentage of the tube numbers in untreated control wells.
Statistical Analysis
All data were expressed as mean 6 SD. Three to five separate experiments were performed for each study. Data were analyzed by Student's t test or ANOVA with Tukey post hoc tests (SPSS version 11.5; SPSS, Chicago, IL). Statistical significance was set at P < 0.05.
RESULTS

CD47 Mediates TSP-induced Cytotoxicity in Cerebral Endothelial Cells
Cytotoxic effects of CD47 were evaluated with standard assays for MTT and LDH release. Exposure to the CD47 ligand TSP-1 (100 to 1,000 ng/ml) for 24 hr induced increasing amounts of cell death in primary cultured wild-type cerebral endothelial cells. Compared with this wild-type response, levels of endothelial cytotoxicity were significantly reduced in CD47 knockout mouse cells (Fig. 1A) . Of course TSP-1 can bind other receptors besides CD47. So we sought to further confirm our findings with 4N1K, a CD47-specific activating peptide. Exposure to 4N1K (25 to 100 lg/ml) for 24 hr similarly induced a cytotoxic response in human brain endothelial cells (Fig. 1B) . However, we failed to detect a clear dose response in this case. Only the highest concentration of 4N1K (100 lg/ml) yielded a statistically significant cytotoxicity.
TSP Up-regulated the Inflammatory Markers ICAM-1 and VCAM-1
To assess the effects on inflammation, we measured responses of three representative endothelial cell adhesion molecules: ICAM-1, VCAM-1 and E-selectin. Exposure of human brain endothelial cells to low concentrations of TSP-1 (500 ng/ml) triggered a rapid and clear up-regulation in ICAM-1 and VCAM-1 within 2 to 8 hr (Fig. 2) . However, no changes are detected for E-selectin (Fig. 2) .
4N1K Inhibits Endothelial Cell Migration and Tube Formation In Vitro
Confluent monolayers of human brain endothelial cells were subjected to scratch wounds, and then incubated with the CD47-specific peptide 4N1K (100 lg/ ml) for 24 hr. Compared with untreated controls, 4N1K significantly suppressed endothelial cell migration by almost 50% (Fig. 3A,B) . On a standard Matrigel assay, the human brain endothelial cells underwent spontaneous alignment over 18-20 hr, and fused into continuous tubes with distinct lumens to form capillary-like structures (Fig. 4A) . Compared with untreated cultures, 4N1K significantly reduced the formation of tubes by about 40%-50% (Fig. 4B ).
DISCUSSION
The neurovascular unit provides a conceptual framework wherein stroke is investigated as an integrative pathophysiology of both vascular and neuronal compartments Iadecola, 2004; Zlokovic, 2005; Abbott et al., 2006; Lok et al., 2007) . The importance of this concept has been supported by many recent studies showing that common signals and substrates underlie neuronal and vascular biology (Mazzone and Carmeliet, 2008) . And after cerebral ischemia, most neuronal mediators can also participate in vascular responses and vice versa (Greenberg and Jin, 2005; Lazarovici et al., 2006) . Here, we propose that the integrin-associated protein CD47 may play such a dual role as well. CD47 is known to induce cell death in neurons (Koshimizu et al., 2002; Xing et al., 2009) . In the present study, we demonstrated that CD47 signaling triggered cell death in brain endothelial cells, promoted the inflammatory up-regulation of cell adhesion molecules, and suppressed angiogenesis in vitro.
Historically, brain endothelial cells, unlike neurons, were thought to be relatively resistant to ischemic challenge (Gobbel et al., 1994; Plateel et al., 1995) . However, accumulating data now suggest that endothelial cell death can occur after cerebral ischemia, and these vascular events play critical roles in the progression of brain damage after stroke (Lee and Lo, 2003; Zhang et al., 2005; Fisher, 2008) . We recently showed that CD47 may trigger caspase-dependent and caspase-independent neuronal death ). Here, we found that CD47 signaling similarly mediated cell death in brain endothelial cells. This broader neurovascular ability of CD47 to trigger cell death is consistent with the literature. Others have reported that the activation of CD47 by the endogenous ligand TSP-1 or the peptide 4N1K triggers complex cell death pathways in a wide range of cell types such as T cells, leukemia cells, monocytes, and breast tumor cells (Mateo et al., 1999; Frazier, 2003, 2004; Johansson et al., 2004 ; Saumet et al., Fig. 1 . CD47-mediated TSP-1-induced cytotoxicity in endothelial cells. A: Exposure to CD47 ligand TSP-1 for 24 hr induced an increasing amount of cell death in wild-type cerebral endothelial cells. TSP-1-induced cytotoxicity was significantly decreased in brain endothelial cells from CD47 knockout mice. B: CD47-specific activating peptide 4N1K similarly induced a cytotoxic response in human brain endothelial cells. *P < 0.05, **P < 0.01 compared with the controls;ˆP < 0.01 between wild-type and CD47 knockout groups. Fig. 2 . TSP-1 up-regulates the expression of ICAM-1 and VCAM-1 in brain endothelial cells. Exposure of human brain endothelial cells to a low dose of the CD47 ligand TSP-1 (500 ng/ml) triggers an upregulation in the inflammatory markers ICAM-1 and VCAM-1 within 2 to 8 hr. No changes are detected for E-selectin; n 5 3 independent experiments in triplicate. *P < 0.05 compared with controls.
2005). Because CD47-mediated cell death occurs via multiple pathways, one might speculate that blocking the CD47 signal can productively ameliorate a wide spectrum of cell death mechanisms.
CD47 is well recognized as a multifactorial mediator in blood physiology, especially as a mediator of leukocyte and neutrophil transmigration across endothelial barriers (Cooper et al., 1995; Lindberg et al., 1996; Fig. 3 . The CD47 activating peptide 4N1K inhibits cell migration in brain endothelial cells. A: Representative photographs showed decreased migration of human brain endothelial cells across a wound scratch line after treatment with 4N1K (100 lg/ml). B: Quantified cell counts showed a significant difference in cell migration between controls and 4N1K-treated cells. **P < 0.01. Demeure et al., 2000; Hagnerud et al., 2006) . In the context of stroke, this property may significantly contribute to the neuroinflammation that is thought to amplify secondary damage after ischemia and reperfusion. Here, we showed that activation of CD47 very rapidly (within 2-8 hr) up-regulated two important markers of endothelial inflammation, i.e. ICAM-1 and VCAM-1. This finding is consistent with previous studies showing that CD47 signaling increased levels of adhesion molecules in endothelial cells (Narizhneva et al., 2005) , but with one difference. In human umbilical vein endothelial cells (HUVECS) and aortic endothelial cells, the expressions of ICAM-1, VCAM-1 and selectins were all elevated by CD47 activation. In contrast, E-selectin was unchanged in our brain endothelial cells. This may point to interesting differences between the routes taken by inflammatory cells when crossing brain endothelial barriers vs. other endothelial cells in the body. Nevertheless, our findings here suggest that CD47 may be a potential target for preventing neurovascular inflammation in stroke.
The concept of the neurovascular unit may apply not only during acute stages of stroke and brain injury, but also during delayed phases of stroke recovery (Lo, 2008a) . Brain ischemia stimulates a coordinated response in angiogenesis and neurogenesis within days to weeks after stroke (Chen et al., 1994; Parent, 2003; Greenberg and Jin, 2005) . A close interaction between remodeling vessels and plastic neuronal networks is central to stroke recovery (Ohab et al., 2006; Slevin et al., 2006; Thored et al., 2007) . In this context, the CD47 ligand TSP-1 may be especially important. TSPs are a family of multidomain, calcium-binding extracellular glycoproteins and comprise five genes encoding proteins, TSP-1 through TSP-5 (Adams and Lawler, 2004) . TSP-1 plays a major role in cell-matrix and cell-cell interactions that influence platelet function, angiogenesis, tumor biology, wound healing, and vascular disease (Esemuede et al., 2004) . TSP-1 is a potent inhibitor of angiogenesis (Lawler and Detmar, 2004) . But, traditionally, the inhibition of angiogenesis and the induction of apoptosis in microvascular endothelial cells by TSP-1 were thought to be mediated via the CD36 receptor (Dawson et al., 1997; Jimenez et al., 2000) . Our findings here suggest that CD47 plays a key role in these antiangiogenic and endothelial-toxic responses as well. More recently, other labs have reported several parallel pathways. CD47 appears to be necessary for inhibition of nitric oxidestimulated vascular cell responses by TSP-1 (Isenberg et al., 2006) . And the proliferation of microvascular endothelial cells can be inhibited by the interaction of TSP-1 with very low density lipoprotein receptor (VLDLR) (Oganesian et al., 2008) . In contrast to these antiangiogenic phenomena, TSP-1 may also bind ApoER2 (apolipoprotein E receptor 2) and VLDLR to promote neuronal migration (Blake et al., 2008) . Thus, TSP-1 signaling might yield opposite effects in vascular vs. neuronal compartments. Nevertheless, our present study is consistent with vasculosuppressive mechanisms of TSP-1-CD47 signaling. The CD47-activating peptide 4N1K clearly inhibited the migration of brain endothelial cells, and suppressed Matrigel tube formation in vitro. Because endogenous angiogenesis is important in remodeling brain, CD47 pathways can potentially interfere with stroke recovery as well.
Taken together, our data suggest that CD47 induces multiple deleterious effects in brain endothelial cells that may contribute to the pathophysiology of stroke. However, several caveats and potential limitations must be acknowledged. First, this is clearly a proof-of-concept study in cells. Further in vivo data must be obtained to support these cellular findings. Second, although we demonstrate that the CD47 signaling induces endothelial death, we do not know the precise pathways involved. In neurons, nonoverlapping caspase and free radical mechanisms are involved . Further studies are warranted to dissect the mechanisms of CD47-mediated endothelial cytotoxicity. A third limitation relates to the role of other receptors. As discussed endogenous mediators such as TSP-1 can activate multiple receptors including CD47 and CD36. How these receptors work together remains to be carefully elucidated. Finally, our study cannot provide a complete activation paradigm. CD47 can be activated by multiple ligands such TSP or signal regulatory proteins. Soluble TSP-1 is a major component of platelet granules and is released upon platelet activation (Mosher et al., 1992) . Which mediators are important in stroke? Are there both autocrine and/or paracrine pathways? How these signals interact will have to be sorted out rigorously.
An emerging consensus in the field is that saving neurons alone may not suffice for stroke. An optimal stroke therapy must comprise simultaneous targeting of multiple pathways in multiple cell types. Functional interactions between all cell types in the neurovascular unit must be salvaged, including neuronal, glial and vascular elements (Dewar et al., 2003; Rossi et al., 2007; Lo, 2008b; Zlokovic, 2008) . Indeed, many ongoing efforts in this field are now pursuing multi-target and multi-pathway therapies. Examples may include minocycline (Yong et al., 2004) , activated protein C (Griffin et al., 2002; Thiyagarajan et al., 2008) , erythropoietin (Brines and Cerami, 2005) , hypothermia (Yenari et al., 2008) , and other diverse methods to induce ischemic tolerance and preconditioning (Gidday, 2006) .
In this context, we propose that CD47 might represent an interesting neurovascular target for stroke therapy because it may play critical roles at multiple steps in the ischemic cascade. CD47-mediated platelet aggregation may worsen thrombosis and lead to additional ischemia. Activated platelets can release soluble TSP-1, which goes on to trigger even more CD47 pathways. CD47 on affected brain endothelium may up-regulate ICAM-1, VCAM-1 and allow the infiltration of inflammatory cells. Once the signals reach the brain, CD47 can trigger cell death in both endothelium as well as neurons. Finally, CD47 may also suppress stroke recovery because it inhibits angiogenesis. Thus, one might speculate that successful and carefully titrated blockade of deleterious CD47 signals may influence both acute and delayed outcomes.
In conclusion, our study suggests that CD47 can induce cell death, promote inflammation, and suppress angiogenic responses in brain endothelial cells. Further studies to dissect and validate CD47 mechanisms in vivo are warranted.
